Apogee Therapeutics Inc. (APGE)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
Apogee Therapeutics, Inc. (APGE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Apogee Therapeutics, Inc. (APGE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Apogee Therapeutics, Inc. (APGE) Discusses Positive Part B Results From Phase 2 APEX Trial of Zumilokibart in Atopic Dermatitis Transcript
Apogee Therapeutics, Inc. (APGE) Discusses Positive Part B Results From Phase 2 APEX Trial of Zumilokibart in Atopic Dermatitis Transcript
Apogee Therapeutics: Charging Toward Pivotal Eczema Trial With Extended Dosing
Apogee Therapeutics, Inc. remains a Buy, driven by zumilokibart's potential in atopic dermatitis and recent positive Phase 2b data. Zumilokibart's efficacy matches leading biologics, with the key differentiator being 2–4 annual doses, pending maintenance data in 2025. The Blackstone collaboration secures up to $1.3B in funding, eliminating near-term dilution risk and supporting commercialization.
Apogee Therapeutics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CE Curtis Ellergodt Rothschild Investment LLC | 77 | $3,273.99 | $10,334.94 | $7,060.95 | 215.67% |
| BG Bart Gancher Intech Investment Management LLC | 12,210 | $541,337.98 | $1.64M | $1.1M | 202.61% |
 David Kim Paradigm Biocapital Advisors LP | 1.35M | $66.68M | $180.94M | $114.26M | 171.34% |
| NM Nir Messafi Deep Track Capita LLP | 285,000 | $23.99M | $38.25M | $14.26M | 59.44% |
 Joseph Castro Nuveen LLC | 128,115 | $6.56M | $17.19M | $10.64M | 162.25% |
Apogee Therapeutics Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| GM Geoff Meacham B of A Securities | 377.53 | $19,782.55 | $50,698.43 | $30,915.88 | 156.28% |
Apogee Therapeutics Inc. (APGE) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Apogee Therapeutics Inc. ever had a stock split?
Apogee Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Michael Thomas Henderson CEO | NASDAQ (NMS) Exchange | 03770N101 CUSIP |
| US Country | 261 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Apogee Therapeutics, Inc. is a biotechnology firm focusing on the discovery and development of advanced biologics aimed at treating a range of conditions linked to atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and other related inflammatory and immunologic diseases. Incorporated in 2022, the company leverages its expertise in monoclonal antibodies to devise treatments that address unmet needs within these therapeutic areas. With its headquarters located in Waltham, Massachusetts, Apogee Therapeutics operates through its subsidiary, striving to bring innovative solutions from laboratory to clinic.
Products and Services
APG777 - A subcutaneous (SQ) extended half-life monoclonal antibody (mAb) targeting atopic dermatitis (AD). APG777 represents Apogee's commitment to offering novel therapeutic options for AD patients, providing a potentially improved pharmacokinetic profile that could enhance efficacy and patient compliance by reducing the frequency of dosing.
APG808 - An innovative SQ extended half-life monoclonal antibody developed for the treatment of chronic obstructive pulmonary disease (COPD). APG808 underscores the company's focus on respiratory diseases, aiming to provide COPD patients with a more effective and convenient treatment regimen.
APG990 - Another of Apogee's early-stage projects, APG990 is an SQ extended half-life mAb designed for AD treatment. Similar to APG777, this developmental product reinforces the company's dedication to addressing the complex needs of AD patients through enhanced therapeutic agents.
APG222 - Focused on AD, APG222 is part of Apogee's portfolio of extended half-life SQ antibodies. Although in the earlier stages of development compared to APG777 and APG990, APG222 highlights the company's ongoing efforts to expand its offerings in dermatological conditions, providing foundation for future innovations in treatment modalities.
